argenex SE $ARGX Shares Bought by CenterBook Partners LP

CenterBook Partners LP raised its holdings in argenex SE (NASDAQ:ARGX) by 2,473.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,226 shares of the company’s stock after buying an additional 11,751 shares during the quarter. CenterBook Partners LP’s holdings in argenex were worth $11,724,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC raised its position in argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after purchasing an additional 83,568 shares in the last quarter. First Trust Advisors LP boosted its holdings in argenex by 98.9% during the first quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock valued at $78,279,000 after purchasing an additional 53,293 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in argenex by 314.8% during the second quarter. Squarepoint Ops LLC now owns 58,400 shares of the company’s stock valued at $54,182,000 after purchasing an additional 44,321 shares in the last quarter. Peregrine Capital Management LLC bought a new stake in shares of argenex in the 2nd quarter valued at approximately $27,584,000. Finally, Hsbc Holdings PLC bought a new stake in shares of argenex in the 1st quarter valued at approximately $14,882,000. Institutional investors own 60.32% of the company’s stock.

argenex Stock Up 3.6%

ARGX stock traded up $32.44 during trading on Friday, hitting $927.21. The company had a trading volume of 378,409 shares, compared to its average volume of 506,127. The firm has a 50-day moving average price of $930.66 and a 200-day moving average price of $857.30. argenex SE has a 12 month low of $661.85 and a 12 month high of $1,072.75. The stock has a market cap of $58.31 billion, a price-to-earnings ratio of 32.35, a PEG ratio of 0.81 and a beta of 0.48.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping analysts’ consensus estimates of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The firm had revenue of $1.75 billion during the quarter. Equities analysts expect that argenex SE will post 28.41 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. DZ Bank restated a “buy” rating on shares of argenex in a research report on Friday, October 9th. Sanford C. Bernstein reiterated a “buy” rating on shares of argenex in a research report on Thursday, October 8th. Citizens Jmp increased their price objective on argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 18th. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a report on Sunday, October 25th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of argenex in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, argenex presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,158.76.

argenex Company Profile

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs.

Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy.